https://www.live-feeds.com/feed/exclusive-openai-has-acquired-orchestra-bioContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/exclusive-openai-has-acquired-orchestra-biohttps://www.live-feeds.com/feed/exclusive-openai-has-acquired-orchestra-bio#u151193Sat, 24 Oct 2026 07:51:11 +0000OpenAI has acquired biotech startup Orchestra Bio to accelerate drug development timelines and integrate artificial intelligence agents into pharmaceutical research workflows. The acquisition brings Orchestra Bio's team and technology into Rosalind, OpenAI's life sciences research platform. Founded in 2022, Orchestra Bio builds tools and intelligent management platforms that coordinate drug discovery processes and help pharmaceutical teams manage research delays. The exact financial terms of the deal were not disclosed, though the startup had previously raised about $20 million from